Jonathan A. Fletcher, M.D.
This page shows the publications co-authored by Jonathan Fletcher and Chandrajit Raut.
Correction: Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours. Br J Cancer. 2019 Jul; 121(3):281.
Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours. Br J Cancer. 2019 03; 120(6):612-620.
MAX inactivation is an early event in GIST development that regulates p16 and cell proliferation. Nat Commun. 2017 03 08; 8:14674.
Dystrophin is a tumor suppressor in human cancers with myogenic programs. Nat Genet. 2014 Jun; 46(6):601-6.
MED12 mutations in leiomyosarcoma and extrauterine leiomyoma. Mod Pathol. 2013 May; 26(5):743-9.
Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network. Ann Oncol. 2020 11; 31(11):1506-1517.
Genomic aberrations in cell cycle genes predict progression of KIT-mutant gastrointestinal stromal tumors (GISTs). Clin Sarcoma Res. 2019; 9:3.
Gastrointestinal stromal tumor enhancers support a transcription factor network predictive of clinical outcome. Proc Natl Acad Sci U S A. 2018 06 19; 115(25):E5746-E5755.
Thyroid hormone inactivation in gastrointestinal stromal tumors. N Engl J Med. 2014 Apr 03; 370(14):1327-34.
Aberrant AKT activation drives well-differentiated liposarcoma. Proc Natl Acad Sci U S A. 2011 Sep 27; 108(39):16386-91.
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.